In order to correlate biomarker changes to the clinical outcome, the relative changes between cycle 1, day 14 and baseline for VEGF, bFGF, tumour blood flow and tumour vessel permeability as measured by DCE-MRI (r2 = 0.0025, ρ = 0.050, p = 0.7769; Figure 2d), and diastolic blood pressure were correlated to the best tumour shrinkage reached during therapy. This evidence concerns the gene FGF2 and neoplasm.